Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Antifungal Agent
34%
Posaconazole
32%
Voriconazole
28%
Invasive Aspergillosis
23%
Therapeutic Drug Monitoring
21%
Infection
20%
Pharmacodynamics
20%
Pyrrole
18%
Amphotericin B
16%
Fluconazole
15%
Disease
14%
Micafungin
11%
Aspergillus fumigatus
11%
Isavuconazole
10%
Antifungal Therapy
10%
Caspofungin
10%
Anidulafungin
10%
Normal Human
9%
Mycosis
8%
Lung Aspergillosis
8%
Systemic Mycosis
8%
Tacrolimus
7%
Vancomycin
7%
Ciprofloxacin
7%
Itraconazole
6%
Flucloxacillin
6%
Aspergillosis
6%
Drug-Drug Interaction
6%
Pyrrole Derivative
6%
Prevalence
6%
Echinocandin
6%
Minimum Inhibitory Concentration
6%
Aspergillus
5%
Infectious Agent
5%
Volume of Distribution
5%
Antiinfective Agent
5%
Clinical Trial
5%
Pharmacokinetic Modeling
5%
Keyphrases
Pharmacokinetics
46%
Voriconazole
28%
Posaconazole
28%
Critically Ill Patients
24%
Therapeutic Drug Monitoring
23%
Invasive Aspergillosis
14%
Liposomal Amphotericin B
12%
Pharmacodynamics
12%
Target Attainment
12%
Antifungal Drugs
11%
Isavuconazole
11%
Population Pharmacokinetics
10%
Micafungin
10%
Fluconazole
10%
Anidulafungin
10%
Caspofungin
10%
Antifungal Therapy
10%
Oncology Patients
10%
Azoles
9%
Pharmacokinetic Study
9%
Aspergillus Fumigatus
9%
Intensive Care Unit Patients
9%
Plasma Concentration
9%
Dosing Regimen
9%
Morbid Obesity
8%
Population Pharmacokinetic Model
8%
Ciprofloxacin
8%
COVID-19-associated Pulmonary Aspergillosis
8%
Drug Interactions
8%
Invasive Pulmonary Aspergillosis
8%
Flucloxacillin
8%
COVID-19
8%
Obesity
7%
Invasive Fungal Disease
7%
Tacrolimus
7%
Renal Function
7%
Dried Blood Spots
7%
Pharmacokinetics-pharmacodynamics (PK-PD)
7%
Invasive Fungal Infection
7%
Obese Men
7%
Minimum Inhibitory Concentration
7%
Trough Concentration
7%
Antimicrobial
6%
Antifungal Prophylaxis
6%
Pediatric Patients
6%
Azole Antifungals
6%
Dosing Recommendations
6%
Non-obese
6%
High Dose
6%
Azole-resistant
6%
